Actorius Innovations And Research

Executive Summary

Actorius Innovations and Research is an Indian biotech company specializing in liquid biopsy and circulating tumor cell (CTC) technologies for early cancer detection and intervention. Its flagship OncoDiscover® test detects and enumerates CTCs from a simple 5 ml blood sample, enabling non-invasive monitoring across multiple solid tumor types. The company also developed OncoDialysis®, a therapeutic system designed to filter CTCs from the bloodstream, potentially reducing metastatic burden. Founded in 2013 and based in Pune, India, the company has achieved commercial-stage operations with a lean team of 10–50 employees, targeting both diagnostic and therapeutic oncology markets. Actorius addresses the growing demand for cost-effective, minimally invasive cancer management tools in India and globally. While its technologies offer compelling advantages in accessibility and real-time monitoring, commercial adoption remains early-stage, with limited publicly disclosed revenue or partnership data. The company's dual focus on detection and removal differentiates it from pure-play liquid biopsy firms, but successful commercialization will depend on regulatory approvals, clinical validation, and strategic collaborations. Given the large addressable market and unmet need for early cancer detection, Actorius holds potential as a niche player, though execution risks persist due to limited scale and competition from established diagnostics companies.

Upcoming Catalysts (preview)

• Q3 2026Regulatory approval of OncoDialysis® system by CDSCO (India)70% success
• Q4 2026Strategic partnership with a major hospital network for OncoDiscover® adoption60% success
• Q2 2026Publication of multi-cancer clinical validation study for OncoDiscover®80% success